new glp-1 medications Eli Lilly to seek approval of weight-loss drug this year A new study from the
Description
GLP-1 acts on receptors in your brain to dampen feelings of hunger, which can reduce appetite and how many calories you take in
Two classes of newer anti-hyperglycemic agents can reduce CV risk and events in patients with T2D, namely glucagon-like peptide-1 receptor agonists (GLP-1RA) and sodium-glucose cotransporter-2 (SGLT-2) inhibitors
Patients should be aware of potential side effects like nausea or gastrointestinal discomfort, but these effects often subside over time
Specifically, study participants taking GLP-1 drugs had a 10% lower risk of depression than participants taking DPP4i medication
